Finnrick, an independent testing programme, publishes 23 assays for LP Peptide: 7 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 16 did not. Most recent assay 3 Aug 2026.
LP Peptide listed by Finnrick as "Trading", has no storefront on record — Finnrick lists only a messaging or social contact. Source: Finnrick, https://www.finnrick.com/vendors/lp-peptide.
Listed in the Finnrick vendor directory. Not yet tested.
LP Peptide is listed as active. Tracked by Finnrick. No test data available yet.
| Product | Assays | Result |
|---|---|---|
| Retatrutide | 11 | 4 passed, 7 failed |
| GHK-Cu | 6 | 3 passed, 3 failed |
| Tesamorelin | 6 | 0 passed, 6 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Vendor type | Research-use supplier |
These details were read from LP Peptide's own website on 2026-08-10. Pages consulted:
LP Peptide is listed as active and we hold 23 Finnrick assays (7 passing, 16 failing its purity threshold). That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 23 assays for LP Peptide: 7 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 16 did not. Most recent assay 3 Aug 2026.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: LSPL Peptides Review, Lumex Health Peptides Review, Lumira Peptides Review.